Navigation Links
Indevus Announces Submission of New Drug Application
Date:8/28/2007

ancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Indevus Reports Positive Data From Phase III NEBIDO Trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... reimbursement rates for home medical equipment and services (HME) ... as a result of Medicare,s bidding program going into ... largest metropolitan areas in the U.S. ... City, Miami, Orlando, Pittsburgh, and Riverside, California. The bidding ...
... Pa., Dec. 16, 2010 West Pharmaceutical Services, Inc. (NYSE: ... approved payment of the first-quarter 2011 cash dividend of $0.17 per ... shareholders of record on January 19, 2011. ... components and systems for injectable drug delivery, including stoppers and seals ...
Cached Medicine Technology:Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 2Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 3
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... , , CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... way to fight invasive fungal infections, which kill about 1.5 million ... of action of amphotericin, an antifungal drug that has been in ... nearly as toxic to human cells as it is to the ...
Breaking Medicine News(10 mins):Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... physician and hospital is decreasing, study finds, , , TUESDAY, April ... physician would be the one who directed your health care ... comfort level. , But, in reality, that type of seamless ... Americans. , A new study found that among Medicare patients, ...
... pillow giveaway and Danny Seo appearance on HSN. , ... ... Earth Day, Simmons Bedding Company is encouraging consumers to ... the company,s Natural Care® mattress and pillow collection, which is endorsed ...
... RONKONKOMA, N.Y., April 21 NBTY, Inc. (NYSE: NTY ... marketer of nutritional supplements, today announced it will web cast a ... Web site, ( www.NBTY.com ), on Friday, April 24, ... for the fiscal second quarter will be issued at 4:30 PM ...
... CHAPEL HILL, N.C., April 21 New research with ... and managed markets is now available in the Best ... and consulting firm Best Practices, LLC.To review key topics ... links to each of the two new studies at ...
... WASHINGTON, April 21 FRC Action ... the Senate Finance Committee approved Gov. Kathleen Sebelius,s nomination ... vote on Gov. Sebelius,s nomination reflects growing grassroots opposition ... her failure to disclose deep financial ties to late-term ...
... Nursing baby brings cardiovascular benefits decades later, study suggests, ... just good for baby, it may also boost mom,s ... , Women in their 60s who had breast-fed for ... 10 percent less likely to develop cardiovascular disease, and ...
Cached Medicine News:Health News:Transition From Home to Hospital Rarely Seamless 2Health News:Transition From Home to Hospital Rarely Seamless 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 2Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 4Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 5Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 2Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 3Health News:Best Practice Database Adds Research Highlighting Effective Data Gathering Approaches for Competitive Intelligence and Successful Activities for Gaining Maximum Payer Access and Insights 2Health News:Breast-feeding a Boon to Mom's Heart 2Health News:Breast-feeding a Boon to Mom's Heart 3
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of total and direct bilirubin in serum or plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: